Cargando…
What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?
Anti-vascular endothelial growth factor (VEGF) therapy has revolutionised the treatment of retinal disease, and appears to be very safe. Nevertheless, there are several lines of evidence that imply that small doses of these agents could potentially have a systemic effect. The clinical significance o...
Autor principal: | Avery, Robert L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033205/ https://www.ncbi.nlm.nih.gov/pubmed/24326326 http://dx.doi.org/10.1136/bjophthalmol-2013-303844 |
Ejemplares similares
-
The effect of intravitreal anti-VEGF agents on peripheral wound healing in a rabbit model
por: Christoforidis, John, et al.
Publicado: (2012) -
Current Evidence for the Prevention of Endophthalmitis in Anti-VEGF Intravitreal Injections
por: Lau, P. ET., et al.
Publicado: (2018) -
The remote effects of intravitreal anti-VEGF therapy
por: Balta, F, et al.
Publicado: (2016) -
Adjunct Intravitreous Triamcinolone Acetonide in the Treatment of Diabetic Macular Edema with Anti-VEGF Agents
por: Garoon, Robert B., et al.
Publicado: (2016) -
Incidence of endophthalmitis after intravitreal injection of an anti-VEGF agent with or without topical antibiotics
por: Morioka, Masakazu, et al.
Publicado: (2020)